Press Releases

Press Releases

August 29, 2018

Application Designated as Class 2 by U.S. FDA and Assigned February 2, 2019 PDUFA Date IRVINE, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced the acceptance of its resubmission of its Biologics License Application

August 17, 2018

IRVINE, Calif. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today announced that Health Canada has granted approval of DWP-450 (prabotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe glabellar lines

August 2, 2018

IRVINE, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a company dedicated to aesthetic medicine, today reported financial results for the second quarter ended June 30, 2018. Second Quarter 2018 and Recent Highlights: Announced early resubmission to the U.S.

July 18, 2018

IRVINE, Calif. , July 18, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today the pricing of its public offering of 4,000,000 shares of common stock at a public offering price of $20.00 per share, before underwriting discounts and commissions.  The offering consists of

July 16, 2018

IRVINE, Calif. , July 16, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) and commenced a proposed underwritten public offering of 5,000,000 shares of its

Displaying 1 - 10 of 28